SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01730911

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Quick Start Insertion of Mirena and ParaGard Intrauterine Contraceptive Devices

Intrauterine devices (IUDs) are an effective form of contraception, but only about 3.4% of women in the US report using them. Women must often wait for their menses to start, or for results of screening for sexually transmitted infections (STIs), before their doctors will place IUDs for them. This is not the case with other birth control methods. Researchers know that it is safe to start oral contraceptive pills, transdermal patches or vaginal rings on the same day of a doctor's visit. In the investigators clinical practice, the investigators often place IUDs on the same day of a woman's visit, but outcomes have not been formally assessed. Currently, there are two kinds of IUDs available in the United States: the ParaGard T380A and the Mirena levonorgestrel intrauterine system (LNG-IUS). The investigators want to know if women who have IUDs placed at any time during their menstrual cycle have different experiences regarding the following, compared to those who have IUDS placed during the first 7 days of their cycle: bleeding or cramping patterns, active pelvic infections, becoming pregnant more often during that first cycle (window pregnancy). Women who come to their provider seeking an IUD for birth control will be asked to participate in this study. The investigators will ask them to keep track of their bleeding and cramping for three subsequent months to see if patterns differ according to the day in their menstrual cycle that the device was inserted. They will be randomly assigned either to record this information on paper, or to send in the information by responding to daily text messages. The investigators want to know if women who have an IUD placed at any time during the menstrual cycle have different outcomes compared to those who have IUDs placed during the first 7 days of their cycle. If the investigators have this information, the investigators can make recommendations to physicians, help counsel patients, and potentially expand access to IUDs.

NCT01730911 Bleeding Cramping Pregnancy With IUD in Place IUD Expulsion IUD Removal
MeSH: Hemorrhage Muscle Cramp Spasm
HPO: Hyperkinesis Muscle spasm

1 Interventions

Name: Text message

Description: Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.

Type: Other

ParaGard, text message Mirena, text message


Primary Outcomes

Measure: Number of bleeding and cramping days

Time: 3 months

Purpose: Health Services Research

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 T380A

Currently, there are two kinds of IUDs available in the United States: the ParaGard T380A and the Mirena levonorgestrel intrauterine system (LNG-IUS). --- T380A ---



HPO Nodes


HPO:
Hyperkinesis
Genes 13
PNKD GNE YME1L1 ALDH5A1 TRAPPC11 PTS SLC9A6 GCH1 GNAO1 NGLY1 PSAP PRRT2 PDE10A
Muscle spasm
Genes 129
PMP22 VAPB TRPM6 COL4A1 DPAGT1 MPZ CACNA1S TRAPPC11 AMPD1 AMPD3 PSAT1 MYH7 ERBB4 CHCHD10 DNAJC13 HINT1 UBQLN2 ANG REEP1 SLC25A4 FKRP RRM2B POLG DOK7 MATR3 FLVCR1 ANXA11 GARS LRRK2 MAP3K20 LAMA2 PON1 GBA PON2 PON3 DAO ABCB6 CRPPA CASQ1 TWNK CASR OPA3 LAMP2 POMT1 CAV3 PFKM CPT2 PFN1 MORC2 LDHA TFG DCTN1 PGAM2 HNRNPA1 RTN2 PGK1 AR GFPT1 PHGDH ALG2 RYR1 CHRNE CHMP2B STIM1 CCNF NEFH FBXO38 KY PPARGC1A TARDBP ORAI1 NEK1 OPTN KCNA1 ATP6 GLA SLC12A1 SLC12A3 CLCNKB SLC16A1 ATXN2 FIG4 WASHC5 FKTN GLE1 FDX2 SQSTM1 KCNJ1 ALG14 DGUOK TBK1 ISCU SCN4A VPS35 EIF4G1 ATXN3 TREM2 MFN2 ALDH18A1 GIGYF2 DLD PYGM SMN1 GNA11 BSCL2 TAF15 HADHA HADHB FUS GNAS KCNJ18 ATP1A1 DMD SNCA C9ORF72 POLG2 TRNW STX16 DNA2 GMPPB ATP2A1 UNC13A CFAP410 HSPB1 SOD1 VCP EPHA4 GABRA3 PRPH